List view / Grid view


Drug Target Review – Issue #3 2016

20 September 2016 | By Drug Target Review

In Issue #3 2016: Flow Cytometry, Enzymes, Imaging, GPCRs, Hit-To-Lead, CNS, Companion Diagnostics, and much more...

Hit-To-Lead In-Depth Focus 2016

20 September 2016 | By Drug Target Review

In this Hit-To-Lead In-Depth Focus: Hit-to-lead in drug discovery; Zebrafish early-life stages as neurological screening and detection tools...

Switching on genes regulating oxysterol synthesis – a therapeutic option?

20 September 2016 | By

Cholesterol is a ubiquitous molecule that, while essential for health, is probably best known as a risk factor for cardiovascular disease. It is also the obligate precursor for a wide range of metabolites, from steroid hormones to bile acids. Although studied for more than 100 years, recently there has been…

High-throughput calcium flux assays: luminescent versus fluorescent readout

20 September 2016 | By , , ,

In vitro high-throughput cellular target-based assays are commonly used for hit identification targeting G-protein coupled receptors (GPCR). Agonist and antagonist identification of GPCRs often relies on the screening of large collections of chemicals using miniaturised in vitro cell-based functional assays. In the panel of assays, calcium mobilisation measured by aequorin…

Fibromyalgia pathogenesis provides drug target clues

20 September 2016 | By

Fibromyalgia (FM) has been described as a condition of heightened generalised sensitisation to sensory input presenting as a complex of symptoms dominated by chronic widespread pain characterised by hyperalgesia and allodynia. A range of co-morbidities of variable intensity, such as fatigue, sleep disturbance, cognitive impairment, anxiety and depression, are often…